The development of covalent ligands for G proteincoupled receptors (GPCRs) is not a trivial process. Here, we report a streamlined workflow thereto from synthesis to validation, exemplified by the discovery of a covalent antagonist for the human adenosine A 3 receptor (hA 3 AR). Based on the 1H,3Hpyrido[2,1-f ]purine-2,4-dione scaffold, a series of ligands bearing a fluorosulfonyl warhead and a varying linker was synthesized. This series was subjected to an affinity screen, revealing compound 17b as the most potent antagonist. In addition, a nonreactive methylsulfonyl derivative 19 was developed as a reversible control compound. A series of assays, comprising time-dependent affinity determination, washout experiments, and [ 35 S]GTPγS binding assays, then validated 17b as the covalent antagonist. A combined in silico hA 3 AR-homology model and site-directed mutagenesis study was performed to demonstrate that amino acid residue Y265 7.36 was the unique anchor point of the covalent interaction. This workflow might be applied to other GPCRs to guide the discovery of covalent ligands.
■ INTRODUCTION
The adenosine A 3 receptor (A 3 AR) is one of four G proteincoupled receptor subtypes stimulated by adenosine. 1 Different from the other subtypes (A 1 , A 2A , and A 2B ) A 3 AR was identified by molecular biology studies prior to its pharmacological characterization. 2 The initial studies indicated its important role in both physiological and pathophysiological conditions, such as cell proliferation, cell differentiation, neuroprotection, cardioprotection, and apoptosis. 3 Nevertheless, the medical relevance of the human adenosine A 3 receptor (hA 3 AR) is enigmatic due to its dichotomy in different therapeutic applications. 3 In this regard, there is a continuing interest in the development of selective ligands of the hA 3 AR to investigate its pharmacological effects. For instance, selective A 3 AR antagonists have been applied for the treatment of glaucoma 4 and respiratory tract inflammation such as asthma. 5 In particular, a tricyclic xanthine derivative, 1benzyl-8-methoxy-3-propyl-1H,3H-pyrido[2,1-f ]purine-2,4dione (compound 1, Figure 1A ), has been reported to exert high affinity for the hA 3 AR. 6−8 Initial efforts to study the structural biology of GPCRs suffered from numerous limitations, such as low expression, dynamic conformational states, and inherent instability. Covalent ligands, i.e., compounds that irreversibly bind to the receptor and possess a reactive moiety to target specific amino acid residues, helped to solve some of these obstacles. 9 This is also the case for adenosine receptors. For example, the structure of the human adenosine A 1 receptor, having the highest similarity to the hA 3 AR among all adenosine receptor subtypes (61% of sequence homology), 10 has been elucidated by X-ray crystallography with a covalent antagonist DU172 (2) ( Figure 1B ). 11 However, the application of covalent ligands in hA 3 AR studies has been limited to the characterization of the receptor type, 12−14 far from providing a comprehensive study of receptor structure elucidation, pharmacological characteristics, and ligand−receptor binding description.
To this end, we devoted our efforts to the discovery of a well-defined covalent antagonist based on xanthine analogue 1 mentioned above. Inspired by the resemblance in the chemical structure between the potent hA 3 AR antagonist 1 and irreversible adenosine A 1 receptor antagonist 2, we incorporated the reactive moiety, a fluorosulfonyl benzoyl group, connected to a spacer, at the N 1 position of the scaffold. Using a structured approach to bring the reactive fluorosulfonyl group in close proximity to a nucleophilic amino acid residue, we diversified the type of linker, linker length, and position of the fluorosulfonyl substituent on the phenyl group, resulting in a series of analogues with a wide range of affinities. Our efforts led to the discovery of a best-in-class antagonist, 17b, which is bound to the hA 3 AR with an apparent affinity in the nanomolar range. To retain the chemical structure similarity, we replaced the warhead with a methylsulfonyl moiety to obtain a nonreactive derivative 19 as a reversible control compound. 17b was then validated to covalently bind and inactivate the hA 3 AR in an insurmountable manner. Molecular modeling suggested the fluorosulfonyl functionality of 17b in close proximity to Y265 7.36 , which was identified as the unique anchor point of the covalent interaction in a subsequent mutagenesis study. The confirmed binding mode between this novel covalent antagonist and hA 3 AR opens the door for exploring other ligand binding motifs and will benefit receptor stabilization and further structure elucidation of the hA 3 AR.
■ RESULTS AND DISCUSSION
Design of Covalent hA 3 AR Antagonists. In previous studies, our research group disclosed several series of hA 3 AR antagonists based on the pyrido[2,1-f ]purine-2,4-dione scaffold. 6−8 Using compound 1, a nanomolar probe from the previous series, as the starting point, we further designed and synthesized compounds based on a previously suggested binding mode of the pyrido[2,1-f ]purine-2,4-dione scaffold. 7 When examining the suggested binding mode of this scaffold, we noted that this scaffold inserted into the binding pocket with a receptor interaction between TM3, TM6, and EL2. Two key H-bonds include the carbonyl-oxygen at the C 4 -position with residue N250 6.55 and the methoxy substituent at the C 8position bonding to Q167 EL2 . Taking this into account, we reasoned that the only available space to incorporate the reactive warhead is limited to N 1 -position substituents.
To explore the chemical space required to optimally position the warhead in close proximity to a nucleophilic amino acid residue, we examined various linker systems, connecting the warhead and the pyrido[2,1-f ]purine-2,4-dione scaffold. First, variation in the length of the spacer, between two and four carbon atoms, may offer more steric freedom allowing the fluorosulfonyl group to orient toward an adjacent nucleophilic residue in the receptor binding site. 15, 16 Additionally, the type of chemical bond connecting the warhead to the spacer was varied between the slightly differently oriented ester or amide Scheme 1. Synthetic Route toward Scaffold 7 a a bond. Finally, since the exact position of an appropriate nucleophilic residue is unknown, the sulfonyl fluoride moiety was positioned at either the 3-or 4-position of the phenyl ring. To this end, four series of compounds 13a−c, 14a−c, 17a−c, and 18a−c, bearing three different spacer lengths, ester or amide linkage, and 3-or 4-fluorosulfonylphenyl warhead were targeted for synthesis.
Synthesis. Scaffold. The scaffold, 8-methoxy-3-propyl-1H,3H-pyrido-[2,1-f ]purine-2, 4-dione (1), was synthesized according to the previously published procedure. 6−8 Starting from the commercially available benzylurea (3), the fused tricyclic intermediate (6) was generated by excess Nbromosuccinimide (NBS) bromination and 4-methoxypyridine cyclization (Scheme 1). Then, alkylation at the N 3 -nitrogen by 1-bromopropane in dry dimethylformamide (DMF), using dry potassium carbonate as a weak base, afforded the reference compound (1) in 73% yield. Removing the benzyl protecting group by palladium hydroxide afforded the fused xanthine core (7) .
Ester Linker. The fluorosulfonyl warhead is notorious for its reactivity, resulting in undesired side reactions or hydrolysis under several harsh reactions. 17 So, we adopted a convergent synthetic strategy in which the fluorosulfonylphenyl linker unit was prepared separately and attached directly to scaffold 7 at the N 3 position. This approach offers flexibility to accommodate a variety of different linker lengths. The warhead was synthesized from commercially available chlorosulfonylbenzoic acids (8a and 8b) (Scheme 2), followed by a 2 M solution of potassium bifluoride treatment to afford fluorosulfonylbenzoic acids (9a and 9b) in good yields. 18 The next step converted the carboxylic acids to acid chlorides (10a and 10b) by excess thionyl chloride treatment. These acyl chlorides are susceptible to hydrolysis and were thus used in the next step reaction without further purification. To incorporate the acyl chlorides with the corresponding bromoalkylalcohols, compounds 10a and 10b were heated to 100°C with the addition of bromoalkylalcohols to afford the desired bromoalkyl fluorosulfonylbenzoates (11a−c and 12a−c) in decent yields. The final step was to couple the core to the corresponding bromoalkyl fluorosulfonylbenzoates. To preserve the functional fluorosulfonyl group, the reactions were carried out under mild conditions at low temperatures. Additionally, Amide Linker. A similar synthetic approach was initially pursued to prepare analogues with an amide linker. However, the basicity and instability of bromoalkylamine caused complex side reactions with itself and with the warhead, ending up with an unacceptably low yield of amide-linked building blocks. An alternative synthetic route was devised, where 1-phthalimidopropyl bromide was attached directly to the N 3 position of scaffold 6, to afford the substituted intermediates 15a−c (Scheme 3). Liberation of the amine took place by treatment with hydrazine monohydrate in methanol to obtain compound 16a−c in moderate yield. Then 16b and 16c were acylated with acyl chlorides 10a and 10b, respectively, to obtain 17c and 18b. However, impurities brought by the acylation reaction were not easily removed by column chromatography or preparative thin-layer chromatography (TLC). To overcome this, we used peptide coupling conditions with the corresponding benzoic acids (9a and 9b) to convert the free amine to the target compounds (17a,b, 18a, and 18c) in good yields (Scheme 3). A similar synthetic strategy was adapted to obtain reversible ligand 19 as a control compound.
Pharmacological Evaluation. Determination of the Apparent Affinity (K i ) of Synthetized Ligands. To determine the binding affinity for the hA 3 AR, all compounds were tested in a radioligand displacement binding assay in the presence of 10 nM [ 3 H]PSB-11 at 25°C according to previously reported procedures. 7, 19 All compounds were able to concentration-dependently inhibit specific [ 3 H]PSB-11 binding to the hA 3 AR. As detailed in Table 1 , all putative covalent compounds, except the two carbon linker compounds (13a, 14a, 17a, and 18a), displayed high affinities for the hA 3 AR (K i < 100 nM). It should be mentioned that the putative covalent nature of the interaction between the hA 3 AR and ligands precludes the determination of equilibrium binding parameters. Therefore, we expressed the ligands' affinity for the hA 3 AR as "apparent K i ". Of note, 17b, bearing three carbon atoms with amide linkage and positioning the sulfonyl fluoride at the 4-position of the phenyl ring, interacted with the hA 3 AR with comparable affinity (10 nM) as the parent compound 1. High affinity is desirable for covalent ligand design, as it allows sufficient receptor occupancy with the electrophilic warhead in proximity to a nucleophilic residue in the binding site over time, concomitant with putatively negligible or less interaction with off-targets. Thus, we chose compound 17b for further studies. However, featuring an electrophilic fluorosulfonyl functionality, 17b was no longer a close analogue of compound 1, whereas a nonreactive control compound, chemically similar to the designed covalent ligand, is needed for the further pharmacological characterization.
A nonsubstituted phenyl to replace the warhead might impose different steric and electronic characteristics of the ligand. To avoid this, we performed a conservative structural modification to replace the reactive warhead with an electronwithdrawing methylsulfonyl group, yielding derivative 19 as a nonreactive control compound. 
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To better understand the time-dependent binding characteristics of these compounds, we carried out radioligand displacement assays under two different protocols. In detail, the CHO cell membranes overexpressing the hA 3 AR were either preincubated with the indicated compound for 4 h, followed by a 0.5 h co-incubation or only co-incubated for 0.5 h with the radioligand [ 3 H]PSB-11. As detailed in Table 2 , both compounds had comparable binding affinity in the low micromolar range (pK i = 6.9 ± 0.06 for 17b and pK i = 6.2 ± 0.03 for 19) at 0.5 h incubation time. However, compound 17b showed a significantly increased affinity (pK i = 8.0 ± 0.01) when it was preincubated with the hA 3 AR, whereas the affinity of compound 19 did not change (pK i = 6.1 ± 0.06). The effect of preincubation on the affinity of 17b and 19 is illustrated in Figure 2 , i.e., the [ 3 H]PSB-11 displacement curve was shifted to the left with an increased incubation time for compound 17b (Figure 2A ), whereas no difference was observed for compound 19 ( Figure 2B) .
Presumably, this time-dependent binding affinity of compound 17b (i.e., resulting from an increased receptor occupancy over time) is a result of an increasing level of covalent binding. Similar results on other GPCRs, such as β 2 adrenergic receptor 20 and A 2A adenosine receptor, 21 showed that covalent bond formation generates an increased affinity over time. Meanwhile, control compound 19 showed no substantial pK i shift in affinity at the two incubation times, indicating that a dynamic equilibrium was achieved at both incubation times. We can thus speculate that the possible covalent interaction between compound 17b and the receptor may be attributed to the presence of a reactive warhead.
Finally, we tested 17b and 19 for their affinity on the other adenosine receptor subtypes and learned that the two compounds were at least modestly selective for the hA 3 AR ( Table 2) .
Kinetic Characterization of the Covalent Ligand. Subsequently, the significant shift in apparent K i drove us to explore the binding kinetic profile of 17b at the hA 3 AR, specifically its dissociation rate and residence time (RT). Previously, the k on (k 1 = 0.281 ± 0.04 × 10 8 M −1 min −1 ) and k off (k 2 = 0.3992 ± 0.02 min −1 ) values of [ 3 H]PSB-11 at 25°C had been determined in our laboratory by traditional association and dissociation assays. Here, we performed a competition association assay to characterize the binding kinetics of 17b and 19 following previously reported procedures from our research group. 7 Using the on-and offrate constants from [ 3 H]PSB, the k on (k 3 ) and k off (k 4 ) values for 17b were determined using the equations from the (equilibrium) Motulsky and Mahan model. 22 17b had a much slower association rate (k on = 3.48 ± 0.22 × 10 5 M −1 min −1 ) than the radioligand and a negligible dissociation rate (k off = 1.38 ± 0.22 × 10 −12 min −1 ), yielding an almost infinite residence time (RT = 7.63 ± 1.19 × 10 11 min), indicative of irreversible receptor binding by 17b. The inadequacy of the Motulsky−Mahan equations to fit this data is further evidence for the nonequilibrium features of the binding of 17b to the receptor. Compound 19 showed fast association and dissociation rate constants ( Figure 3 ). Unfortunately, the data did not converge in the fitting procedure, possibly due to the low binding affinity of compound 19 (K i = 525 nM).
As detailed in Figure 3 , the control curve represented the association curve of radioligand [ 3 H]PSB-11 alone, approaching equilibrium over time. Compound 19 equally associated with and dissociated from the receptor and reached equilibrium within 30 min, evidenced by the same curve shape as the control curve. Of note, 17b's behavior caused an initial "overshoot" of the competition association curve, followed by a linear decline over time indicating that no equilibrium was reached. The shape of 17b's kinetic curve is a quintessential example for the irreversible interaction, similar to the reported covalent ligands' behavior for the adenosine A 2A receptor 21 and mGlu2 receptor. 23 Wash-Resistant Interaction between 17b and hA 3 AR. Inspired by the negligible dissociation of compound 17b from the hA 3 AR, we performed a "washout" experiment to ascertain the irreversible binding between the ligand and the receptor. A protocol previously reported by our laboratory 21 was adapted. We first exposed hA 3 AR cell membranes to 17b or 19 both at 10-fold K i for 2 h, and without washing the samples were supplemented with [ 3 H]PSB-11 to assess the competitive binding capacity of the receptor ("control group" in Figure 4 ).
For washed samples, hA 3 AR cell membranes were subjected to four-cycle washing steps to remove unbound ligand following the preincubation ("4× wash group" in Figure 4 ), after which the membranes were exposed to [ 3 H]PSB-11 to determine the remaining binding capacity. In the absence of the ligand (labeled "+ vehicle" in Figure 4 ), we normalized membranes' binding ability to 100%. Following preincubation with 17b, membranes containing the hA 3 AR lost most of the ability to bind to the radioligand (11.3 ± 1.2% binding remaining). Furthermore, after the preincubation, membranes were washed by cycles of centrifugation in an attempt to regenerate binding Figure 3 . Competition association assay of [ 3 H]PSB-11 in the absence (control) or presence of 17b and 19 at the indicated concentration. Association and dissociation rate constants for the unlabeled ligands were calculated by fitting the data to the equations described in the Experimental Section ("data analysis"). Representative graphs are from one experiment performed in duplicate. Figure 4 . hA 3 AR membranes preincubated with buffer (vehicle) or a 10 × K i concentration of indicated ligand, followed by no washing (control) or four-cycle washing treatment (4× wash) before being exposed to [ 3 H]PSB-11. Data represent the mean ± SEM of three individual experiments performed in duplicate, normalized to the vehicle (set at 100%). Statistics were determined using unpaired Student's t-test. NS: no significant difference, ****P < 0.0001, significant difference between indicated groups.
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Article capacity. However, washing steps failed to restore hA 3 AR binding of [ 3 H]PSB-11 (8.7 ± 3.8%). This was in contrast to preincubation of the hA 3 AR-expressing membranes with ligand 19, in which binding function was completely restored from 19.8 ± 4.7 to 97.6 ± 4.5% following four washing steps. This result indicates that 19 is a reversible ligand which can be rapidly washed off the membranes, whereas 17b forms a washresistant bond between the ligand and the receptor. Similar experiments on other GPCRs, such as adenosine A 1 24,25 and A 2A 21 receptors and the metabotropic glutamate receptor 2 (mGluR2), 23 demonstrated that the covalent interaction between the ligand and the receptor resulted in a washresistant bond formation.
Insurmountable Antagonism Caused by Covalent Interaction. To further evaluate the effect of irreversible inhibition by covalent ligand 17b on receptor function, we performed a membrane functional assay using [ 35 S]GTPγS, which is a typical readout for the activation of receptor-coupled G i/o proteins. 26 Pretreatment of the hA 3 AR with increasing concentrations of ligand 17b, prior to the stimulation with hA 3 
Cl-IB-MECA), produced rightward shifts of agonist concentration−response curves with a concomitant decline in maximal stimulation ( Figure 5A ). Therefore, the covalent ligand 17b generated insurmountable antagonism in the preincubation experiment. In contrast, pretreatment of the hA 3 AR with 19, followed by 2-Cl-IB-MECA agonist exposure resulted in surmountable antagonism ( Figure 5B ), i.e., shifting dose−response curves to the right with no alteration of its maximum effect. The extent of the shifts was used to construct a Schild plot as previously described, 7 which would have a slope of unity if the interaction is competitive and the pA 2value corresponds to the pK i value of the antagonist. The slope for 19 was found to be 1.1 ± 0.1 and the compound's pA 2 value was 5.9 ± 0.1, comparable with its pK i value (6.3 ± 0.03), suggesting that 19 competed with 2-Cl-IB-MECA for the same receptor binding site.
To unravel the molecular mechanism responsible for the insurmountable antagonism of 17b, we also co-incubated either 17b or 19 with the hA 3 
Article antagonism. The Schild plot showed that both antagonists inhibited receptor activation in a competitive manner, with their Schild-slopes close to unity (1.1 ± 0.1 for 17b, 1.0 ± 0.1 for 19, Table 3 ). In addition, 19's pA 2 value was in agreement with that from the preincubation experiments (6.2 ± 0.1, Table  3 ), and the pA 2 value of 17b was also comparable with its pK i value (7.4 ± 0.1 vs 8.0 ± 0.05). Taken together, both ligands fully competed with 2-Cl-IB-MECA bound to the hA 3 AR.
Notably, it is likely that the insurmountable behavior relates to the covalent binding of 17b due to an irreversible blockade that reduces the total receptor population available.
Binding Model for 17b in the hA 3 AR Receptor-Binding Pocket. To examine the interaction between receptor residues possibly involved in covalent binding, we docked 17b into a ligand optimized homology model on the basis of the A 2A receptor crystal structure (PDB: 4EIY 27 ), as described 36 cell membranes were pretreated with buffer (vehicle) or 10 × IC 50 of compound 17b for 2 h followed by no washing (control) or four-cycle washing treatment (4× wash) before being exposed to [ 3 H]PSB-11. Data represent the mean ± SEM of three individual experiments performed in duplicate, normalized to the vehicle (set at 100%). NS: no significant difference between groups; ***Significant difference between groups (P < 0.001); Student's t-test.
Article previously. 7 As detailed in Figure 6 , the core structure of compound 17b interacted with the TM3, TM6, and EL2 regions. Additionally, the carbonyl-oxygen at the C 4 -position participated in H-bond formation with residue N250 6.55 and the methoxyl moiety at the C 8 -position functioned as H-bond acceptor with Q167 EL2 . Interestingly, the latter is a unique residue in the hA 3 AR, as it is not conserved in other subtypes of adenosine receptors. Due to the flexibility of the three carbon linkers, the tyrosine residue Y265 7.36 is in close proximity of the ligand, and could therefore interact with the 4-fluorosulfonylbenzoic warhead to form a covalent sulfonyl amide. Similarly, the same residue Y271 7.36 located within the human adenosine A 1 receptor has also been reported to covalently interact with the fluorosulfonyl warhead of compound 2. 11 Comparison of the binding modes of compound 2 and ligand 17b in an A 1 /A 3 receptor overlay showed that key interactions between ligands and binding sites are preserved, such as a hydrogen bond with N 6.55 ( Figure S1 ). Y265 7.36 as an Anchor Point for the Covalent Bond. Based on the docking study, we postulated that Y265 7.36 is the anchor point for covalent bond formation. To investigate our hypothesis this tyrosine was mutated to phenylalanine (hA 3 AR-Y265F 7.36 ), to remove the nucleophilic reactivity of the phenolic hydroxyl group. First, we performed standard [ 3 H]PSB-11 displacement assays to investigate the binding affinity of 17b and 19 using CHO-K1 cell membranes transiently transfected with either wild type (hA 3 AR-WT) or mutant receptors (hA 3 AR-Y265F 7.36 ). As shown in Table 2 and Figure 7 , the affinity of control compound 19 on hA 3 AR-Y265F 7.36 (pIC 50 = 6.09 ± 0.11) was similar to the affinity to hA 3 AR-WT (pIC 50 = 5.95 ± 0.03), indicating that the mutation has no impact on the binding affinity of the reversible ligand. In marked contrast, 17b's affinity was decreased nearly 43-fold relative to the WT, from an IC 50 value of 27 to 1072 nM, indicative of the loss of irreversible interaction. Moreover, there were no marked affinity differences on hA 3 AR-Y265F 7.36 between 17b and 19. This suggests that the chemically dissimilar ligands 17b (reactive) and 19 (nonreactive) exhibit a similar binding interaction with hA 3 AR-Y265F 7.36 . We thus speculate that the amino acid in position 7.36 plays a prominent role in the covalent bond formation between the fluorosulfonyl warhead and the receptor. To support this idea, we repeated the washout assay on hA 3 AR-Y265F 7.36 . Membranes treated with 17b at 10-fold IC 50 inhibited the specific [ 3 H]PSB-11 binding to 7.2 ± 0.6%. After extensive washing, hA 3 AR-Y265F 7.36 showed a complete recovery of [ 3 H]PSB-11 binding to 91 ± 2% ( Figure 7C ). This full recovery for mutant hA 3 AR-Y265F 7.36 is in sharp contrast to the findings in the wild-type washout assay (Figure 4) , indicating that Y265F 7.36 completely prevented the washresistant bond formation. In other words, Y265 7.36 is the unique amino acid residue involved in the covalent attachment of 17b's fluorosulfonyl group within the hA 3 AR binding pocket. A similar approach was also adopted to pinpoint the anchor point between covalent probes and other subtypes of GPCRs, such as the adenosine A 2A receptor, 21 mGlu2 receptor, 23 and cannabinoid CB 1 receptor. 28 17b can be a useful structural biology tool as it would be expected to stabilize the 7TM domain in its inactive state, thereby potentially facilitating crystallization of the receptor material. This could be highly valuable for the structure elucidation of the hA 3 AR, which up to now remains unreported. Furthermore, understanding the precise molecular interactions between the ligand and the receptor may stimulate the more rational design of novel ligands. Such ligands may have improved receptor subtype selectivity, fewer undesirable side effects, and enhanced potency and efficacy, leading to potentially attractive therapeutic agents that produce their effects by modulating the functionality of the adenosine system. Given that GPCR-targeted covalent drugs went through clinical success across various indications, 29 our covalent compound 17b may serve as a probe to explore the problematic translation of hA 3 AR ligands into the clinical utility in certain disease states such as eye disorder glaucoma, in which an increased A 3 adenosine receptor mRNA and protein levels have been detected.
■ CONCLUSIONS
By introducing a reactive sulfonyl fluoride warhead onto the 1benzyl-3-propyl-1H,3H-pyrido [2,1-f ]purine-2,4-dione scaffold, we designed and synthesized a series of novel covalent hA 3 AR antagonists. Compound 17b acted as the most potent antagonist, with a time-dependent apparent affinity in the low nanomolar range. Meanwhile, we removed the warhead and inserted a methylsulfonyl moiety into the scaffold, to obtain ligand 19 as a reversible control compound. Ligand 17b was then validated as a covalent antagonist through its washresistant nature and insurmountable antagonism in [ 35 S]GTPγS binding assays. In silico homology-docking suggested that Y265 7.36 is responsible for the covalent interaction. Site-directed mutagenesis showed that removal of the nucleophilic tyrosine phenolic hydroxyl group resulted in the complete loss of covalent binding, validating that Y265 7.36 is the only anchor point of reactive covalent ligand 17b. The results contribute to a better understanding of pharmacological behaviors caused by covalent interaction with GPCRs. In the end, we developed a structured approach to quickly obtain a well-defined covalent ligand. Besides, we envisioned that a methylsulfonyl replacement would be suitable for providing a nonreactive sulfonyl-bearing control compound. The rational design of covalent probes may have further value in receptor structure elucidation or in new technologies such as affinitybased protein profiling 15, 30 with the perspective of imaging or structurally probing GPCRs.
■ EXPERIMENTAL SECTION
Chemistry. All solvents and reagents were purchased from commercial sources and were of analytical grade. Demineralized water is simply referred to as H 2 O, and was used in all cases unless stated otherwise (i.e., brine). 1 H were recorded on a Bruker AV 400 liquid spectrometer ( 1 H NMR, 400 MHz) at ambient temperature and 13 C NMR spectra were recorded on a Bruker AV 600 liquid spectrometer ( 13 C NMR, 125 MHz) at indicated temperature. 
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Article 80:10:10. All final compounds showed a single peak at the designated retention time and are at least 95% pure. Liquid chromatography− mass spectrometry (LC−MS) analyses were performed using a Thermo Finnigan Surveyor−LCQ Advantage Max LC−MS system and a Gemini C18 Phenomenex column (50 × 4.6 mm 2 , 3 μm). Highresolution mass spectrometry (HRMS) analyses were performed using a Thermo Scientific LTQ Orbitrap XL Hybrid Ion Trap-Orbitrap Mass Spectrometer. The sample preparation was the same as for HPLC and HRMS analyses. The compounds were eluted from the column within 15 min after injection, with a three-component system of H 2 O/MeCN/0.2% TFA in H 2 O, decreasing polarity of the solvent mixture in time from 80:10:10 to 0:90:10. Thin-layer chromatography (TLC) was routinely performed to monitor the progress of reactions, using aluminum-coated Merck silica gel F254 plates. Purification by column chromatography was achieved using the Grace Davison Davisil silica column material (LC60A 30−200 μm). Solutions were concentrated using a Heidolph Laborota W8 2000 efficient rotary evaporation apparatus. All reactions in the synthetic routes were performed under a nitrogen atmosphere unless stated otherwise. The procedure for a series of similar compounds is given as a general procedure for all within that series, annotated by the numbers of the compounds.
1-Benzyl-8-methoxy-3-propyl-1H,3H-pyrido[2,1-f ]purine-2,4-dione (1). 7, 8 To a stirred suspension of 6 (6.0 g, 19 mmol, 1.0 equiv) in MeCN (120 mL) were added 1-bromopropane (5.6 mL, 57 mmol, 3.0 equiv) and DBU (50 mL, 57 mmol, 3.0 equiv). This mixture was stirred at 70°C overnight. The conversion of the starting material was confirmed by TLC (2% MeOH in CH 2 Cl 2 ) and the solvent was removed under vacuum. The residue was suspended in 6-Amino-1-benzyl-1,3-dihydropyrimidine-2,4-dione (5). 7, 8 The synthesis of the compounds was performed as adapted from the procedure reported before. 7, 8 Benzylurea (3) (25 g, 167 mmol, 1.0 equiv) and 4 (16 g, 191 mmol, 1.1 equiv) were dissolved in acetic anhydride (100 mL). This mixture was stirred at 80°C for 2 h. After the mixture was cooled to room temperature, diethyl ether (150 mL) was added followed by 1 h of stirring at room temperature. The precipitate was filtered off and suspended in a mixture of EtOH (75 mL) and H 2 O (150 mL). This mixture was heated to 85°C and 3 M NaOH (aq.) (50 mL) was added dropwise. After 1 h, the mixture was concentrated and neutralized by the dropwise addition of HCl (37%). The precipitate was filtered off and washed with acetone, obtaining 5 as a white solid (9.0 g, 42 mmol, 25%). 1 General Procedure for the Synthesis of Bromoalkyl (fluorosulfonyl)benzoates (11a−c and 12a−c). A mixture of thionyl chloride (8 mL) and fluorosulfonylbenzoic acid (9a,b) (1 equiv) was refluxed at 75°C for 3 h. The solvent was removed under vacuum and the product was used in the next step without further analysis. Dry dioxane (6 mL) was added to the (fluorosulfonyl)benzoyl chloride (10a,b). To this solution, the corresponding bromoalkylalcohol (0.85 equiv) was added and the mixture was refluxed overnight. After the completion of the reaction was observed by TLC (CH 2 Cl 2 ), the volatiles were removed in vacuo and the crude product was purified by column chromatography using CH 2 Cl 2 as an eluent to afford the products. General Procedure for the Synthesis of 13a−c and 14a−c. The synthesis of these compounds was adapted from the conditions previously described by Priego et al. 6 The scaffolds 8-methoxy-3propyl-1H,3H-pyrido[2,1-f ]purine-2,4-dione 7 (1.0 equiv) and K 2 CO 3 (1.6 equiv) were suspended in anhydrous DMF. The mixture was added dropwise to a stirred solution of the corresponding bromoalkyl (fluorosulfonyl)benzoate (11a−c or 12a−c) (1.0 equiv) in anhydrous DMF (4 mL). The reaction was stirred at 50°C overnight. After the conversion was observed by TLC, an excess amount of CH 2 Cl 2 was added. Then the mixture was washed with 1 M HCl (aq.), water, and brine. The organic layer was dried over MgSO 4 , filtered, and concentrated in vacuo. The crude product was
Article purified by column chromatography, followed by prep TLC to further purify the compound if necessary.
2-(8-Methoxy-2,4-dioxo-3-propyl-3,4-dihydropyrido[2,1-f ]purine-1(2H)-yl)ethyl 4-(fluorosulfonyl)benzoate (13a). Prepared from 11a and purified by column chromatography (1% CH 3 OH in CH 2 Cl 2 ) to give the desired product as a white solid (0.038 g, 0.07 mmol, 52%). 1 . EDC (0.12 g, 0.60 mmol, 1.2 equiv) was dissolved in CHCl 3 (4 mL). To this stirring solution was added the acid (9a) (0.11 g, 0.55 mmol, 1.1 equiv). The amine (16a) (0.16 g, 0.50 mmol, 1.0 equiv) was suspended in CHCl 3 (6 mL) and then was added dropwise via an
Article automatic syringe at a rate of 0.2 mL min −1 . The reaction was stirred for 1.5 h at room temperature and monitored by TLC (CH 2 Cl 2 / acetone = 3:2). After completion, the solvent was removed under vacuum and the residue was redissolved in CHCl 3 (40 mL). The organic layer was washed with 1 M HCl (40 mL) and H 2 O (2 × 40 mL), dried over MgSO 4 , and concentrated in vacuo to obtain 17a as a white solid (0.20 g, 0.39 mmol, 78%). 1 Acid 9a (0.11 g, 0.53 mmol, 1.5 equiv) was dissolved in an excess of thionyl chloride (20 mL) at 75°C under nitrogen for 3 h. After removal of solvent and other volatiles under vacuum, 10a was obtained as a colorless oil. Subsequently, amine 16c (0.12 g, 0.35 mmol, 1.0 equiv), K 2 CO 3 (0.073 g, 0.53 mmol, 1.5 equiv), and dry DMF were added and the reaction as stirred at 40°C overnight. After completion of the reaction, 1 M HCl (200 mL) was added and extracted with CH 2 Cl 2 (150 mL). The organic layer was washed with water (100 mL) and brine (100 mL). The organic layer was dried, filtered, and concentrated in vacuo. The residue was purified by column chromatography using CH 2 Cl 2 with 1% methanol as the eluent to give 17c as a white solid (5.0 mg, 0.0094 mmol, 4%). 1 . EDC (0.12 g, 0.60 mmol, 1.2 equiv) was dissolved in CHCl 3 (4 mL). To this stirring solution was added acid 9b (0.11 g, 0.55 mmol, 1.1 equiv). Amine 16a (0.16 g, 0.50 mmol, 1.0 equiv) was suspended in CHCl 3 (6 mL) and then was added dropwise via an automatic syringe at a rate of 0.2 mL min −1 . The reaction was stirred for 3 h at room temperature and monitored by TLC (CH 2 Cl 2 /acetone = 3:2). After completion, the solvent was removed in vacuo and the residue was resolubilized in CHCl 3 (40 mL). The organic layer was washed with 1 M HCl (40 mL) and twice with H 2 O (2 × 40 mL), dried over MgSO 4 , and concentrated in vacuo to give 18a as a white solid (0.17 g, 0.35 mmol, 70%). 1 Acid 9b (0.42 g, 2.0 mmol, 3.0 equiv) was dissolved in thionyl chloride (20 mL) and stirred for 3 h at 75°C. The thionyl chloride was evaporated and the residue was co-evaporated twice with toluene. Then, amine 14b (0.23 mg, 0.7 mmol, 1.00 equiv), K 2 CO 3 (0.073 g, 0.53 mmol, 1.5 equiv), and dry DMF were added and the reaction was stirred at 40°C overnight. 1 M HCl (200 mL) was added and extracted with CH 2 Cl 2 (150 mL). The organic layer was washed with water (100 mL) and brine (100 mL). The organic layer was dried, filtered, and concentrated in vacuo. The residue was purified by column chromatography using CH 2 Cl 2 with 1% methanol as the eluent to give 18b as a white solid (0.0050 g, 0.01 mmol, 2.7%). 1 EDC (0.13 g, 0.69 mmol, 1.2 equiv) was dissolved in CH 2 Cl 2 (3 mL). Acid 9b (0.13 g, 0.63 mmol, 1.1 equiv) was added to this solution and the mixture was stirred. Amine 16c (0.20 g, 0.57 mmol, 1 equiv) was dissolved in CHCl 3 (8 mL) and added dropwise via an automatic syringe at a rate of 0.2 mL min −1 to the stirring solution. After 3 h at room temperature, the reaction was completed and the mixture was concentrated in vacuo. The residue was dissolved in CH 2 Cl 2 (40 mL) and washed with 1 M HCl (40 mL) and twice with H 2 O (2 × 40 mL). The organic layer was dried over MgSO 4 and concentrated in vacuo. Purification by column chromatography (CH 2 Cl 2 /acetone = 3:2) gave 18c as a white solid (0.14 g, 0.26 mmol, 47%). 1 (19) . To a solution of EDC (0.061 g, 0.32 mmol, 1.2 equiv) in CHCl 3 (5 mL) was added 4-(methylsulfonyl)benzoic acid (0.060 g, 0.30 mmol, 1.1 equiv). Amine 16b (0.090 g, 0.27 mmol, 1 equiv) was taken up in CHCl 3 (5 mL) and was subsequently added dropwise via an automatic syringe at a rate of 0.15 mL min −1 . The reaction was stirred at room temperature and monitored by TLC (4% MeOH in CH 2 Cl 2 ). After 3 h, the reaction was completed and CHCl 3 (50 mL) was added. The organic layer was washed with 1 M HCl (60 mL), H 2 O (60 mL), and brine (60 mL), dried over MgSO 4 , and concentrated under vacuum. The product was purified by column chromatography using 2% MeOH in CH 2 Cl 2 to afford the title compound (0.075 g, 0.14 mmol, 54%). 1 ). 13 Computational Studies. All calculations were performed using the Schrodinger Suite. 31 Since compound 17b shares high similarity with the ligands on which we previously published, 7 the same homology model based on the high-resolution antagonist-bound crystal structure of the adenosine A 2A receptor (PDB: 4EIY 27 
